中药防护治疗方案联合化疗治疗非小细胞肺癌临床研究

Clinical study on the combination of traditional Chinese medicine and chemotherapy in the treatment and prevention of non-small cell lung cancer

目的:观察中药防护治疗方案联合化疗治疗非小细胞肺癌的临床疗效和安全性。方法:将80例非小细胞肺癌患者随机分成治疗组和对照组。两组均接受NCCN指南标准连续化疗2个周期(21d为1个周期),治疗组在对照组基础上联合使用中药防护治疗方案(口服中药汤剂+口服中成药+静脉滴注中药注射剂),2个周期后观察两组的瘤体客观疗效、生活质量、不良反应和机体免疫功能。结果:治疗组与对照组瘤体客观疗效有效率分别为38.9%和33.3%,治疗组有效率高于对照组,但是差异无统计学意义;治疗组在提高生活质量、减轻化疗不良反应、改善机体免疫力方面均优于对照组(P<0.01,P<0.05)。结论:非小细胞肺癌患者采用中药防护治疗方案联合化疗的临床疗效优于单纯化疗,值得临床大力推广。

Objective: To evaluate the clinical efficacy and safety of the combination of traditional Chinese medicine and chemotherapy in the treatment and prevention of non-small cell lung cancer. Methods: Eighty cases of non-small cell lung cancer patientswere randomly divided into the treatment group and control group. The two group were given the 2-cycle NCCN guidelines standard chemotherapy regimen(21 days a cycle), and the control group were also given a traditional Chinese medicine(TCM) program(Chinese medicine decoction plus oral administration of Chinese patent medicine plus traditional Chinese medicine injection). After 2-treament period, the tumor, quality of life, toxic and side effects, and the body's immune function were observed. Results: The objective curative effect of tumors in the treatment group and control group were 38.9% and 33.3%, respectively. The effective rate of the treatment group was higher than that of the control group, but there was no difference between the treatment group and control group. The quality of life, toxic and side effects and the body's immune function in the treatment group were significantly superior to those in the control group(P<0.01, P<0.05). Conclusion: The combination of TCM and chemotherapy could improve the clinical efficacy compared with the chemotherapy alone, so it is worth to be promoted.